BMS-986147

BMS-986147 is an orally administered small molecule inhibitor developed by Bristol Myers Squibb. It targets interleukin-1 receptor-associated kinase 4 (IRAK4), a central kinase downstream of Toll-like receptors (TLRs) and interleukin-1 receptors (IL-1Rs), which are involved in immune signaling pathways. By inhibiting IRAK4, BMS-986147 aims to modulate pro-inflammatory cytokine release and neuroinflammation, with potential therapeutic applications in immunological disorders and chronic neuropathic pain. Preclinical studies have shown that BMS-986147 can inhibit TLR-triggered cytokine release and reduce pain behaviors in animal models of nerve injury[2][4]. Clinical development has included phase 1 trials in healthy volunteers to assess safety, pharmacokinetics, and target engagement[5].